Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative zoledronic acid vs no adjuvant therapy in chemo-insensitive breast cancer after neoadjuvant chemotherapy
2004-002355-14Phase 3Completed
- Sponsor
- GBG Forschungs
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoints: Event-free survival and Overall survival. Started Oct 2004; status: completed.
02
Drugs
zoledronic acid
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-002355-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002355-14.